Breast Cancer

Scientists develop new drug to combat tamoxifen-resistant tumors

Published in Women's Health Weekly, April 11th, 2002

An antiestrogen compound discovered only 4 years ago, has been found to inhibit the growth of breast cancer cells using a unique mechanism which enables it to work against tumors that are resistant to other antiestrogens, the 3rd European Breast Cancer Conference in Barcelona (March 2002).

Yasuji Yamamoto, from the Institute of Molecular and Cellular Biosciences at the University of Tokyo in Japan, said the compound, known as TAS-108, was being assessed in phase I clinical trials at the M.D. Anderson Cancer Center, Houston, Texas.

"We believe that TAS-108 is a promising antiestrogen for the treatment of breast cancer patients," said Dr. Tetsuji Asao,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly

Source: Women's Health Weekly (2002-04-11)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry